Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 30.92B, Biogen(BIIB) trades at $213.37. The stock has a price-to-earnings ratio of 22.42.
On 2026-07-29, Biogen(BIIB) stock traded between a low of $206.27 and a high of $218.53. Shares are currently priced at $213.37, which is +3.4% above the low and -2.4% below the high.
Biogen(BIIB) shares are trading with a volume of 2.4M, against a daily average of 1.18M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $124.56.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $124.56.
BIIB News
Revenue Tops Expectations On Growth Across Key Products The Alzheimer’s drug maker reported revenues of $2.736 billion, beating the consensus of $2.458 billion...
Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers' 7/14/2026 Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowe...
Ami Fadia, an analyst from Needham, maintained the Buy rating on Biogen. The associated price target remains the same with $256.00. Unlock powerful investing t...
Analyst ratings
62%
of 37 ratingsMore BIIB News
Advertisement Biogen earnings event and why it matters for shareholders Biogen (BIIB) has just reported second quarter 2026 earnings, giving investors fresh d...
Biogen BIIB reported second-quarter 2026 adjusted earnings per share (EPS) of $3.60, which significantly beat the Zacks Consensus Estimate of $3.04 per share. E...
Biogen Inc. (BIIB) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $4 per share. This compares to earnings of $4.02...
Consensus $11.82. Full year total revenue is now expected to increase by a mid-single digit percentage for 2026 as compared to 2025 driven by continued revenue...
Reports Q2 revenue $2.736B, consensus $2.46B. “This quarter is a reflection of the significant progress Biogen (BIIB) has made repositioning the company for lon...
Biotech and Pharma Earnings Report Biogen Raises Earnings Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs In this article BIIB IONS SPX AMGN NVS...
The second-quarter 2024 reporting cycle of the Medical sector will gain further traction this week. The sector mainly comprises pharma/biotech and medical devic...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.